DOW JONES21,413.44+469.93 2.24%
S&P 5002,526.90+56.40 2.28%
NASDAQ7,487.31+126.73 1.72%

Barclays Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces $32 Price Target

Barclays analyst Gena Wang initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Overweight rating and a $32 price target.

Benzinga · 03/02/2020 11:52

Barclays analyst Gena Wang initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Overweight rating and a $32 price target.